Trials / Recruiting
RecruitingNCT06492876
Gene Therapy for DME
A Dose-escalation and Dose-expanded Phase I/II Clinical Study to Evaluate the Safety, and Efficacy of FT-003 in Subjects With DME
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- Frontera Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with Diabetic Macular Edema (DME). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | FT-003 | Administered via intraocular injection. |
Timeline
- Start date
- 2023-11-15
- Primary completion
- 2024-11-15
- Completion
- 2028-11-15
- First posted
- 2024-07-09
- Last updated
- 2024-07-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06492876. Inclusion in this directory is not an endorsement.